ZimVie announced today that the US Food and Drug Administration has granted Investigational Device Exemption (IDE) for its Mobi-CCervical Disc, which is approved to treat more than one level of the spine.
The IDE approval means ZimVie can begin enrolling participants in a hybrid study following patients who receive simultaneous cervical disc arthroplasty (CDA) and anterior cervical discectomy and fusion (ACDF) —...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?